Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race
Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP receptor antagonist for migraine. The firm is competing with Allergan and Lilly in a race to get the next oral treatment approved.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.